HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroshi Maruyama Selected Research

Melanoma (Melanoma, Malignant)

5/2019Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
11/2018Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
8/2018Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
11/2017Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.
2/2017Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.
1/2017Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment.
9/2016Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
6/2016Nivolumab-induced thyroid dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroshi Maruyama Research Topics

Disease

20Neoplasms (Cancer)
09/2019 - 01/2002
8Melanoma (Melanoma, Malignant)
05/2019 - 06/2016
7Stomach Neoplasms (Stomach Cancer)
04/2022 - 02/2008
7Neoplasm Metastasis (Metastasis)
05/2019 - 02/2008
7Carcinoma (Carcinomatosis)
04/2012 - 05/2003
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2017 - 09/2003
5Esophageal Neoplasms (Esophageal Cancer)
04/2012 - 08/2002
4Vasculitis (Vasculitides)
01/2020 - 04/2016
3Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
01/2020 - 10/2016
3Fabry Disease (Fabry's Disease)
01/2020 - 01/2016
3Microscopic Polyangiitis
01/2020 - 10/2016
3Skin Neoplasms (Skin Cancer)
11/2015 - 11/2011
3Pituitary Neoplasms (Pituitary Adenoma)
11/2013 - 07/2012
3Lymphatic Metastasis
04/2012 - 09/2006
3Adenocarcinoma
03/2009 - 10/2005
2Body Weight (Weight, Body)
08/2022 - 07/2008
2Osteoporosis
03/2021 - 01/2019
2Postmenopausal Osteoporosis
03/2021 - 01/2019
2Infections
02/2021 - 01/2013
2Ascites
04/2019 - 07/2008
2Glomerulonephritis
01/2017 - 01/2013
2Hyperthyroidism
06/2016 - 01/2014
2Fever (Fevers)
06/2016 - 01/2008
2Pathologic Complete Response
03/2015 - 06/2008
2Cysts
01/2015 - 01/2011
2Proteinuria
01/2014 - 01/2013
2Rupture
01/2013 - 10/2004
2Mesothelioma
06/2012 - 04/2012
2Malignant Mesothelioma
04/2012 - 01/2012
2Anorexia
07/2008 - 09/2006
1Albuminuria
08/2022
1Congenital Abnormalities (Deformity)
07/2022
1Drug Hypersensitivity (Drug Allergy)
04/2022
1Head and Neck Neoplasms (Head and Neck Cancer)
10/2021
1Hepatocellular Carcinoma (Hepatoma)
05/2021
1Thrombosis (Thrombus)
05/2021
1Urinary Tract Infections (Urinary Tract Infection)
02/2021
1Pneumonia (Pneumonitis)
02/2021
1Enteritis
02/2021
1Arteriovenous Fistula
11/2020
1Disease Progression
01/2020
1Anemia
05/2019

Drug/Important Bio-Agent (IBA)

7NivolumabIBA
01/2018 - 06/2016
7Fluorouracil (Carac)FDA LinkGeneric
04/2012 - 05/2003
5Docetaxel (Taxotere)FDA Link
04/2012 - 05/2009
5nedaplatinIBA
03/2011 - 05/2003
3GalactosidasesIBA
01/2020 - 01/2016
3Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/2020 - 10/2016
3Monoclonal AntibodiesIBA
05/2019 - 06/2016
3Immune Checkpoint InhibitorsIBA
11/2018 - 09/2016
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2017 - 08/2011
2DenosumabFDA Link
03/2021 - 01/2019
2C-Reactive ProteinIBA
01/2020 - 10/2016
2globotriaosylceramide (globotriosylceramide)IBA
01/2020 - 11/2017
2AntibodiesIBA
05/2019 - 01/2013
2IpilimumabIBA
01/2018 - 11/2017
2SteroidsIBA
11/2017 - 09/2016
2Immunoglobulin G (IgG)IBA
01/2017 - 01/2007
2CreatinineIBA
10/2016 - 01/2013
2Immunoglobulin A (IgA)IBA
04/2016 - 01/2007
2Capsules (Microcapsules)IBA
01/2015 - 01/2013
2Transcription Factors (Transcription Factor)IBA
11/2013 - 05/2013
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2013 - 05/2003
2AutoantibodiesIBA
01/2013 - 01/2007
2ErbB Receptors (EGF Receptor)IBA
06/2012 - 04/2012
2Insulin (Novolin)FDA Link
05/2012 - 05/2004
2Cisplatin (Platino)FDA LinkGeneric
04/2012 - 05/2003
2Irinotecan (Camptosar)FDA LinkGeneric
07/2008 - 09/2006
1Hemoglobins (Hemoglobin)IBA
08/2022
1Sodium-Glucose Transport ProteinsIBA
08/2022
16- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
08/2022
1Sodium-Glucose Transporter 2 InhibitorsIBA
08/2022
1Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2022
1fibrin fragment D (D-dimer)IBA
05/2021
1Anti-Bacterial Agents (Antibiotics)IBA
02/2021
1GlycosphingolipidsIBA
01/2020
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2020
1Tumor Biomarkers (Tumor Markers)IBA
05/2019
1Programmed Cell Death 1 ReceptorIBA
05/2019

Therapy/Procedure

11Drug Therapy (Chemotherapy)
04/2022 - 05/2003
7Lymph Node Excision (Lymph Node Dissection)
10/2017 - 09/2003
7Chemoradiotherapy
11/2013 - 05/2003
5Therapeutics
11/2020 - 09/2006
4Radiotherapy
10/2021 - 05/2003
4Esophagectomy
01/2016 - 09/2003
3Hepatectomy
05/2021 - 01/2011
3Nephrectomy
09/2019 - 02/2008
3Neoadjuvant Therapy
03/2015 - 04/2012
3Argon Plasma Coagulation
11/2010 - 08/2002
3Gastrectomy
07/2008 - 02/2008
2Pedicle Screws
07/2022 - 03/2021
2Catheters
02/2021 - 01/2015
2Cholecystectomy
09/2019 - 01/2011
2Aftercare (After-Treatment)
04/2017 - 06/2008
2Punctures
01/2011 - 05/2008
2Combination Drug Therapy (Combination Chemotherapy)
07/2009 - 05/2009
1Length of Stay
02/2021
1Renal Dialysis (Hemodialysis)
11/2020
1Enzyme Replacement Therapy
01/2020
1Adrenalectomy
09/2019